{
    "title": "U.S. FDA approves Gilead's $94,500 hepatitis C drug",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-2788498/U-S-FDA-approves-Gileads-oral-hepatitis-C-drug.html",
    "date": "2014-10-10",
    "keywords": [
        "hepatitis",
        "c",
        "drug",
        "pill",
        "sovaldi",
        "cost",
        "price",
        "october",
        "inc",
        "express",
        "analyst",
        "percent",
        "market",
        "competition",
        "gmt",
        "email",
        "deena",
        "beasleyoct",
        "friday",
        "course",
        "treatment",
        "brand",
        "name",
        "ledipasvir",
        "need",
        "sideeffectladen",
        "sovaldigilead",
        "backlash",
        "health",
        "interferon",
        "ribavirin",
        "company",
        "product",
        "group",
        "whitrap",
        "spokesman",
        "manager",
        "pharmacy",
        "benefit",
        "premium",
        "pricinghepatitis",
        "disease",
        "inflammation",
        "liver",
        "failuregilead",
        "half",
        "type",
        "regimenthe",
        "street",
        "harvoni",
        "johnson",
        "capital",
        "yee",
        "therapy",
        "bank",
        "robyn",
        "karnauskas",
        "pricing",
        "co",
        "tuesday",
        "approval",
        "twodrug",
        "combination",
        "drugsabbvie",
        "fda",
        "year",
        "application",
        "space",
        "druggilead",
        "reporting",
        "bill",
        "berkrot",
        "york",
        "editing",
        "brown",
        "matthew",
        "lewis"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}